GRFS News and Press, Grifols S.A. From 02/27/23

Grifols S.A. ( NASDAQ: GRFS ) is scheduled to announce FY earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is $0.52 and the consensus Revenue Estimate is $6.25B Over the last 3 months, EPS estimates have seen 0 upward revisions and...

Major earning expected before the bell on Tuesday include: Bank of Montreal ( BMO ) The Bank of Nova Scotia ( BNS ) Cronos Group ( CRON ) Norwegian Cruise Line Holdings ( NCLH ) Target ( TGT ) For further details see: Notable earnings before Tue...

Summary Grifols is a global, Spanish-based biotech company that is a favorite for many European investors, despite the fact that the company does not pay a dividend. It's one of the more well-known Spanish companies on the world stage, with headquarters in Barcelona, an 80+ year history...

Grifols, S.A. ( NASDAQ: GRFS ) ( OTCPK:GIKLY ) ( OTCPK:GIFLF ), an operator of plasma collection centers, announced Wednesday that the company would reduce ~8% of its workforce, mainly in the U.S., in a major cost savings program. The company estimates annualized cost savings ...

Grifols S.A. press release ( NASDAQ: GRFS ): Q3 Revenue of €4.35B. Net profit of €188 million Reported EBITDA totals EUR 927 million For further details see: Grifols S.A. reports Q3 results

Summary RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed phase 3 study might be well received, but it doesn't appear it was. Th...

Spanish biotech Grifols, S.A. ( NASDAQ: GRFS ) ( OTCPK:GIKLY ) ( OTCPK:GIFLF ) announced a long-term agreement with Canada's national blood authority on Wednesday to raise the availability of immunoglobulin (Ig) medicines and plasma-protein therapies in the country. ...

Grifols delivered a mixed quarter on the financial results. But we see some support from the plasma donation evolution. Unlocking Biotest's potential and deleveraging is the priority to check over the next quarters. We were forecasting short-term turbulences but we are still on wi...

Community Health Systems CYH -45% on Q2 results. Coursera COUR -37% on Q2 results. Ranpak Holdings PACK -31% on Q2 results. Teladoc Health TDOC -22% . on Q2 results. Lexicon Pharmaceuticals LXRX -21% on pricing $85M stock offering ...

Agile Therapeutics ( AGRX ) -16% . Bed Bath & Beyond ( BBBY ) -13% on Q1 earnings release . Barnes & Noble Education ( BNED ) -15% on Q4 earnings release . Himax Technologies ( HIMX ) -12% . AeroVironment ( AVAV ) -...